Business
First quarter 2026 update: starting the year on track, with product innovation progress
Louvain-la-Neuve, Belgium, 21 May 2026 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, shares its business update for the first quarter of 2026. Group Overview Solid commercial momentum, particularly in IBA Technologies driven by RadioPharma Solutions, followed by an active pipeline in Proton Therapy.Backlog stable at €1.6 billion, including €0.73 billion and €0.83 billion in equipment and services backlog respectively.FY2026 adjusted EBIT guidance reaffir
About this update from Ion Beam Applications Sa
[{"type":"image","alt":"IBA SA","displaySize":"","headline":null,"caption":"IBA SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":85,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SsPPJL6gCnLwqIjSXOR6Wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTExMA--/https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694","width":85,"height":85},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/SsPPJL6gCnLwqIjSXOR6Wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTExMA--/https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694","width":85,"height":85}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Louvain-la-Neuve, Belgium, 21 May 2026 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, shares its business update for the first quarter of 2026.","length":184,"tagName":"p"},{"type":"text","content":"Group Overview","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Solid commercial momentum, particularly in IBA Technologies driven by RadioPharma Solutions, followed by an active pipeline in Proton Therapy.","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"Backlog stable at €1.6 billion, including €0.73 billion and €0.83 billion in equipment and services backlog respectively.","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"FY2026 adjusted EBIT guidance reaffirmed of at least €32 million, reflecting confidence in the Group’s full-year outlook.","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Net debt position stable at €57 million1 as of March 31, 2026, with €15 million of revolving credit facilities used. Working capital cycle remains driven by large proton therapy project deliveries, with share buyback progress and anticipated supplier payments (related to the new ERP system go-live) further contributing to this evolution. Net financial position expected to remain broadly stable in H1 2026, before progressively improving in H2 2026, with acceleration in 2027.","length":478,"tagName":"p"}]},{"val":[{"type":"text","content":"PanTera reached three key regulatory milestones for pharmaceutical-grade actinium-225 supply, supporting clinical partners in targeted...